280 related articles for article (PubMed ID: 33146973)
21. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
[TBL] [Abstract][Full Text] [Related]
22. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
23. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.
Fossati N; Willemse PM; Van den Broeck T; van den Bergh RCN; Yuan CY; Briers E; Bellmunt J; Bolla M; Cornford P; De Santis M; MacPepple E; Henry AM; Mason MD; Matveev VB; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Lam TB; Mottet N; Joniau S
Eur Urol; 2017 Jul; 72(1):84-109. PubMed ID: 28126351
[TBL] [Abstract][Full Text] [Related]
24. The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer.
Porres D; Pfister D; Thissen A; Kuru TH; Zugor V; Buettner R; Knuechel R; Verburg FA; Heidenreich A
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):85-92. PubMed ID: 27824042
[TBL] [Abstract][Full Text] [Related]
25. Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease.
Badani KK; Reddy BN; Moskowitz EJ; Paulucci DJ; Beksac AT; Martini A; Whalen MJ; Skarecky DW; Huynh LM; Ahlering TE
Urol Oncol; 2018 Jun; 36(6):310.e1-310.e6. PubMed ID: 29625782
[TBL] [Abstract][Full Text] [Related]
26. PSMA-positive nodal recurrence in prostate cancer : Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis.
Schmidt-Hegemann NS; Buchner A; Eze C; Rogowski P; Schaefer C; Ilhan H; Li M; Fendler WP; Bartenstein P; Ganswindt U; Stief C; Belka C; Kretschmer A
Strahlenther Onkol; 2020 Jul; 196(7):637-646. PubMed ID: 32211942
[TBL] [Abstract][Full Text] [Related]
27. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience.
Pierorazio PM; Gorin MA; Ross AE; Feng Z; Trock BJ; Schaeffer EM; Han M; Epstein JI; Partin AW; Walsh PC; Bivalacqua TJ
Prostate; 2013 Nov; 73(15):1673-80. PubMed ID: 24019101
[TBL] [Abstract][Full Text] [Related]
28. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.
Schilling D; Schlemmer HP; Wagner PH; Böttcher P; Merseburger AS; Aschoff P; Bares R; Pfannenberg C; Ganswindt U; Corvin S; Stenzl A
BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442
[TBL] [Abstract][Full Text] [Related]
29. The impact of extended lymph node dissection versus neoadjuvant therapy with limited lymph node dissection on biochemical recurrence in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis.
Narita T; Koie T; Ookubo T; Mitsuzuka K; Narita S; Yamamoto H; Inoue T; Hatakeyama S; Kawamura S; Tochigi T; Habuchi T; Arai Y; Ohyama C
Med Oncol; 2017 Jan; 34(1):1. PubMed ID: 27889880
[TBL] [Abstract][Full Text] [Related]
30. [Salvage lymphadenectomy in patients with prostate cancer recurrence: A review].
Osmonov DK; Aksenov AV; Jilg CA; Schultze-Seeman W; Naumann CM; Hamann MF; Bothe K; Jünemann KP
Urologe A; 2016 Feb; 55(2):208-17. PubMed ID: 26678799
[TBL] [Abstract][Full Text] [Related]
31. Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence.
Suardi N; Briganti A; Salonia A; Rigatti P
Curr Opin Urol; 2011 May; 21(3):237-40. PubMed ID: 21427585
[TBL] [Abstract][Full Text] [Related]
32. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.
Gakis G; Boorjian SA; Briganti A; Joniau S; Karazanashvili G; Karnes RJ; Mattei A; Shariat SF; Stenzl A; Wirth M; Stief CG
Eur Urol; 2014 Aug; 66(2):191-9. PubMed ID: 23735200
[TBL] [Abstract][Full Text] [Related]
33. First case of 18F-FACBC PET/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer and negative 11C-choline PET/CT: new imaging techniques may expand pioneering approaches.
Schiavina R; Concetti S; Brunocilla E; Nanni C; Borghesi M; Gentile G; Cevenini M; Bianchi L; Molinaroli E; Fanti S; Martorana G
Urol Int; 2014; 92(2):242-5. PubMed ID: 24334968
[TBL] [Abstract][Full Text] [Related]
34. [Salvage lymph node dissection for nodal recurrent prostate cancer].
Stolzenbach LF; Knipper S; Maurer T
Aktuelle Urol; 2020 Jun; 51(3):258-264. PubMed ID: 32219775
[TBL] [Abstract][Full Text] [Related]
35. Radiolabeled choline PET/CT before salvage lymphadenectomy dissection: a systematic review and meta-analysis.
Evangelista L; Zattoni F; Karnes RJ; Novara G; Lowe V
Nucl Med Commun; 2016 Dec; 37(12):1223-1231. PubMed ID: 27551835
[TBL] [Abstract][Full Text] [Related]
36. Is More Always Better? An Assessment of the Impact of Lymph Node Yield on Outcome for Clinically Localized Prostate Cancer with Low/Intermediate Risk Pathology (pT2-3a/pN0) Managed with Prostatectomy Alone.
Seyedin SN; Mitchell DL; Mott SL; Russo JK; Tracy CR; Snow AN; Parkhurst JR; Smith MC; Buatti JM; Watkins JM
Pathol Oncol Res; 2019 Jan; 25(1):209-215. PubMed ID: 29079967
[TBL] [Abstract][Full Text] [Related]
37. Initial multicentre experience of
Siriwardana A; Thompson J; van Leeuwen PJ; Doig S; Kalsbeek A; Emmett L; Delprado W; Wong D; Samaratunga H; Haynes AM; Coughlin G; Stricker P
BJU Int; 2017 Nov; 120(5):673-681. PubMed ID: 28548372
[TBL] [Abstract][Full Text] [Related]
38. Lymph node-positive prostate cancer after robotic prostatectomy and extended pelvic lymphadenectomy.
Chenam A; Parihar JS; Ruel N; Pal S; Avila Y; Yamzon J; Lau C; Yuh B
J Robot Surg; 2018 Sep; 12(3):425-431. PubMed ID: 28905289
[TBL] [Abstract][Full Text] [Related]
39. [Indications for pelvic lymphadenectomy in clinically localized prostate cancer].
Peneau M; Villers A; Molinié V; Theis D; Soulié M
Prog Urol; 2004 Jun; 14(3):287-94. PubMed ID: 15373168
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
Maurer T; Gschwend JE; Eiber M
Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
